December, 2017: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2017

December 15, 2017

New Patents Issued Across Multiple Geographies in US, Europe and Japan

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2017) BioAegis Therapeutics announces that during 2017 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in inflammatory disease, neurological disease and renal failure in the United States, Europe and Japan. The plasma gelsolin portfolio now includes 26 issued patents and many pending applications.

December, 2017: BioAegis Therapeutic’s Intellectual Property Portfolio Expands With Six Granted Patents in 2017

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

February 27, 2024: BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

October 16, 2023: BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)

May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

EVENTS

May 23, 2023: Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

COMPANY DETAILS

JOIN OUR TEAM

PRODUCT FAQS

FOLLOW US